Jean-Pierre J. Issa, MD of Fox Chase Cancer Center Fels Institute for Cancer Research & Molecular Biology at Temple University discusses questions of concern on the the toxicity of the new epigenetic drugs and speculation on what happens after treatment with these drugs. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.